The agaricoglycerides are a new class of fungal secondary metabolites that constitute esters of chlorinated 4-hydroxy benzoic acid and glycerol. They are produced in cultures of the edible mushroom, Agaricus macrosporus, and several other basidiomycetes of the genera Agaricus, Hypholoma, Psathyrella and Stropharia. The main active principle, agaricoglyceride A, showed strong activities against neurolysin, a protease involved in the regulation of dynorphin and neurotensin metabolism (IC 50 ϭ200 nM), and even exhibited moderate analgesic in vivo activities in an in vivo model. Agaricoglyceride monoacetates (IC 50 ϭ50 nM) showed even stronger in vitro activities. Several further co-metabolites with weaker or lacking bioactivities were also obtained and characterized. Among those were further agaricoglyceride derivatives, as well as further chlorinated phenol derivatives such as the new compound, agaricic ester. The characteristics of the producer organisms, the isolation of bioactive metabolites from cultures of A. macrosporus, their biological activities, and preliminary results on their occurrence in basidiomycetes, are described.
Keywords agaricoglycerides, pain, fermentation, fungi, in vivo activity
IntroductionNeurolysin (EC 3.4.24.16) is a zinc metalloprotease that inactivates particular biologically active peptides, such as neurotensin and dynorphin A, by specific cleavage [1]. Whereas the kappa-opioid receptor agonist dynorphin A is a well-known and obvious endogenous pain-relieving peptide, neurotensin has been reported to have analgesic properties when applied centrally in animal models [2]. Therefore, neurolysin inhibitors are likely to enhance the analgesic properties of neurotensin and/or dynorphin A by inhibiting cleavage and inactivation of these peptides. Accordingly, selective inhibitors of neurolysin are likely to emphasize the analgesic effects of the aforementioned peptides, which accumulate if their inactivation is prevented. Hence, neurolysin inhibitors appear useful alternatives to complement or substitute therapy with morphine and other opiates in the treatment of severe pain. However, only few specific inhibitors of this target have hitherto been found. Those Bioanalytical Chemistry, GKSS-Forschungszentrum Geesthacht GmbH, Max-Planck-Str. 1, D-21502 Geesthacht/Germany from microbial crude extracts was carried out, followed by identification of bioactive principles from the most promising hits by bioassay-guided fractionation.The current paper deals with the discovery of a new class of biologically active natural products from cultures of edible mushrooms and other basidiomycetes. Their production, isolation, and biological properties are described here, while their physicochemical parameters, structure elucidation, derivatization and total synthesis have been compiled in a patent application [7]. Further details on their structure elucidation will be reported concurrently.
Results and DiscussionIsolation and Biological Activities of Agaricoglycerides (1ϳ4) and Their Co-metabolites...